Wakamoto Pharmaceutical Co.,Ltd.

Tokyo Stock Exchange 4512.T

Wakamoto Pharmaceutical Co.,Ltd. Revenue for the year ending March 31, 2024: USD 51.13 M

Wakamoto Pharmaceutical Co.,Ltd. Revenue is USD 51.13 M for the year ending March 31, 2024, a -21.57% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Wakamoto Pharmaceutical Co.,Ltd. Revenue for the year ending March 31, 2023 was USD 65.19 M, a -5.34% change year over year.
Wakamoto Pharmaceutical Co.,Ltd. Revenue for the year ending March 31, 2022 was USD 68.87 M, a -14.26% change year over year.
Wakamoto Pharmaceutical Co.,Ltd. Revenue for the year ending March 31, 2021 was USD 80.32 M, a -20.89% change year over year.
Wakamoto Pharmaceutical Co.,Ltd. Revenue for the year ending March 31, 2020 was USD 101.53 M, a 4.79% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Tokyo Stock Exchange: 4512.T

Wakamoto Pharmaceutical Co.,Ltd.

CEO	Mr. Arata Igarashi
IPO Date	Jan. 1, 2001
Location	Japan
Headquarters	2-2-2, Nihonbashi Honcho
Employees	403
Sector	Health Care
Industries Pharmaceuticals

Description

Wakamoto Pharmaceutical Co., Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong Wakamoto, a gastrointestinal drug for digestion, intestinal regulation, and nutritional supplementation. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943. Wakamoto Pharmaceutical Co., Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years